Effect of the 5-lipoxygenase inhibitors EP 10045 and EP 10161 on cardiac graft cellular infiltrate and thromboxane formation.
Lim
L K
LK
Department of Surgery, Georgetown University Medical Center, Washington, DC.
Khirabadi
B S
BS
Braquet
P
P
Ramwell
P W
PW
Foegh
M L
ML
D000818:Animals; D001091:Arachidonate Lipoxygenases / Q000037:antagonists & inhibitors*; D001578:Benzopyrans / Q000494:pharmacology*; D002396:Catechols / Q000494:pharmacology*; D002839:Chromans / Q000494:pharmacology*; D003524:Cyclosporins / Q000494:pharmacology; D006084:Graft Rejection / Q000187:drug effects*; D016027:Heart Transplantation; D007962:Leukocytes / Q000473:pathology; D016859:Lipoxygenase Inhibitors; D009206:Myocardium / Q000276:immunology / Q000473:pathology; D051381:Rats; D013440:Sulfides / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000096:biosynthesis*
D001578:Benzopyrans; D002396:Catechols; D002839:Chromans; D003524:Cyclosporins; D016859:Lipoxygenase Inhibitors; D013440:Sulfides; C047171:methyl-2-butylmercapto-4-catechol; C055752:EP 10161; D013929:Thromboxane B2; D001091:Arachidonate Lipoxygenases